News and Analysis
Nature Reviews Drug Discovery 7, 385-386 (May 2008) | doi:10.1038/nrd2579
Fresh from the Pipeline: Rilonacept
Hal M. Hoffman1, Uma Yasothan2 & Peter Kirkpatrick3
Top of page
Abstract
In February 2008, rilonacept (Arcalyst; Regeneron), an interleukin 1 blocker, was approved by the US FDA for the treatment of a group of rare autoinflammatory diseases known as cryopyrin-associated periodic syndromes.
Author affiliations
-
Hal M. Hoffman is at the UCSD School of Medicine, Departments of Pediatrics and Medicine, 9500 Gilman Drive, La Jolla, California 92093-0635, USA.
Email: hahoffman@ucsd.edu -
Uma Yasothan is at IMS Health, 7 Harewood Avenue, London NW1 6JB, UK.
Email: UYasothan@de.imshealth.com -
Peter Kirkpatrick is at Nature Reviews Drug Discovery.
Email: p.kirkpatrick@nature.com
MORE ARTICLES LIKE THIS
These links to content published by NPG are automatically generated.
NEWS AND VIEWS
Inflammation Canakinumab for the cryopyrin-associated periodic syndromesNature Reviews Rheumatology News and Views (01 Oct 2009)
A fever gene comes in from the coldNature Genetics News and Views (01 Nov 2001)
See all 4 matches for News And Views
